Literature DB >> 30846501

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.

Bruno Fattizzo1, Raffaella Pasquale1, Monica Carpenedo2, Silvia Cantoni3, Giuseppe Auteri4, Doriana Gramegna5, Mariella D'Adda5, Mariasanta Napolitano6, Dario Consonni7, Marco Ruggeri8, Sergio Siragusa6, Giuseppe Rossi5, Nicola Vianelli4, Wilma Barcellini9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30846501      PMCID： PMC6886419          DOI： 10.3324/haematol.2019.216804

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Idiopathic thrombocytopenic purpura and dysmegakaryocytopoiesis.

Authors:  Lin Wang; Yuan Li; Ming Hou
Journal:  Crit Rev Oncol Hematol       Date:  2007-09-27       Impact factor: 6.312

Review 2.  Activity of eltrombopag in severe aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety.

Authors:  Jose Ramon Gonzalez-Porras; Jose Maria Bastida
Journal:  Ther Adv Drug Saf       Date:  2018-04-19

4.  Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.

Authors:  Hanny Al-Samkari; David J Kuter
Journal:  Am J Hematol       Date:  2018-09-26       Impact factor: 10.047

Review 5.  Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.

Authors:  Francesco Rodeghiero; Giuseppe Carli
Journal:  Ann Hematol       Date:  2017-03-08       Impact factor: 3.673

6.  Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia.

Authors:  Bruno Fattizzo; Anna Zaninoni; Umberto Gianelli; Alberto Zanella; Agostino Cortelezzi; Austin G Kulasekararaj; Wilma Barcellini
Journal:  Am J Hematol       Date:  2018-01-10       Impact factor: 10.047

7.  Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Authors:  Esther N Oliva; Caterina Alati; Valeria Santini; Antonella Poloni; Alfredo Molteni; Pasquale Niscola; Flavia Salvi; Grazia Sanpaolo; Enrico Balleari; Ulrich Germing; Pierre Fenaux; Aspasia Stamatoullas; Giuseppe A Palumbo; Prassede Salutari; Stefana Impera; Paolo Avanzini; Agostino Cortelezzi; Anna Marina Liberati; Paola Carluccio; Francesco Buccisano; Maria Teresa Voso; Stefano Mancini; Austin Kulasekararaj; Fortunato Morabito; Monica Bocchia; Patrizia Cufari; Maria Antonietta Aloe Spiriti; Irene Santacaterina; Maria Grazia D'Errigo; Irene Bova; Gina Zini; Roberto Latagliata
Journal:  Lancet Haematol       Date:  2017-02-03       Impact factor: 18.959

8.  Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.

Authors:  Leonardo Boiocchi; Attilio Orazi; Waleed Ghanima; Melissa Arabadjief; James B Bussel; Julia Turbiner Geyer
Journal:  Mod Pathol       Date:  2011-08-12       Impact factor: 7.842

9.  The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).

Authors:  Patrizio Mazza; Carla Minoia; Angela Melpignano; Giuseppe Polimeno; Nicola Cascavilla; Nicola Di Renzo; Giorgina Specchia
Journal:  Ann Hematol       Date:  2015-11-24       Impact factor: 3.673

Review 10.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113
View more
  2 in total

1.  Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers.

Authors:  Bruno Fattizzo; Silvia Cantoni; Juri Alessandro Giannotta; Laura Bandiera; Rachele Zavaglia; Marta Bortolotti; Wilma Barcellini
Journal:  Ther Adv Hematol       Date:  2022-05-14

2.  Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.

Authors:  Juan Wang; Min Dai; Qiong Fu; Sheng Chen
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.